Two series of 6-(4-Cl-Phenyl)-4-arylidene-4,5-dihydropyridazin-3(2H)-one (3a-e) and 6-
(4-CH3-Phenyl)-4-arylidene-4,5-dihydropyridazin-3(2H)-one derivatives (3f-j) were synthesized and
evaluated as antitubercular agents against Mycobacterium tuberculosis H37Rv strain by using Microplate
Alamar Blue Assay (MABA) method. These compounds (3a-e & 3f-j) were synthesized from
6-(4-Cl-Phenyl)-4,5-dihydropyridazin-3(2H)-one (2a) and 6-(4-CH3-Phenyl)-4,5-dihydropyridazin-
3(2H)-one (2b) compounds by reacting with appropriate aldehydes respectively. All title compounds
(3a-e & 3f-j) were characterized on the basis of IR, 1HNMR, mass spectral and elemental analysis
data. All title compounds (3a-e & 3f-j) were used at 0.2µg/mL to 100µg/mL dose levels for antitubercular activity. Result
showed that all the title compounds (3a-e & 3f-j) exhibited less antitubercular activity as compared to the reference
drugs streptomycin (MIC value of 6.25µg/mL) and pyrizinamide (MIC value of 3.125µg/mL), except compound 3e,
which was equally effective as streptomycin but less effective than pyrazinamide.
Keywords: Pyridazinone, mycobacterium tuberculosis, infectious disease, antitubercular agents, synthesis, spectral data.
Rights & PermissionsPrintExport